HC Wainwright Lifts Earnings Estimates for Jade Biosciences

Posted by Francis Steltz on Aug 13th, 2026

Jade Biosciences, Inc. (NASDAQ:JBIO – Free Report) – Equities researchers at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of Jade Biosciences in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.57) per share for the quarter, up from their previous forecast of ($0.63). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Jade Biosciences’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Jade Biosciences’ Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.41) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.54) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.56) EPS, FY2027 earnings at ($2.19) EPS, FY2028 earnings at ($2.29) EPS, FY2029 earnings at ($2.33) EPS and FY2030 earnings at ($1.81) EPS.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10).

A number of other equities research analysts also recently issued reports on the stock. Piper Sandler set a $55.00 price objective on shares of Jade Biosciences in a research note on Tuesday, June 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Jade Biosciences in a research note on Tuesday. Weiss Ratings cut Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Guggenheim reaffirmed a “buy” rating and issued a $47.00 target price on shares of Jade Biosciences in a report on Tuesday, June 2nd. Finally, Wall Street Zen cut Jade Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.75.

Check Out Our Latest Report on Jade Biosciences

Jade Biosciences Stock Up 3.8%

JBIO stock opened at $23.21 on Thursday. The company has a market cap of $1.15 billion, a PE ratio of -12.09 and a beta of 1.49. The business has a 50-day simple moving average of $19.95 and a 200 day simple moving average of $18.66. Jade Biosciences has a 52 week low of $6.67 and a 52 week high of $28.00.

Institutional Trading of Jade Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its holdings in Jade Biosciences by 40.3% in the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after purchasing an additional 819 shares in the last quarter. Quantinno Capital Management LP raised its position in Jade Biosciences by 3.6% in the first quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock valued at $429,000 after purchasing an additional 1,059 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Jade Biosciences by 2.9% during the first quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock valued at $542,000 after purchasing an additional 1,086 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Jade Biosciences by 40.7% during the third quarter. Russell Investments Group Ltd. now owns 4,422 shares of the company’s stock valued at $38,000 after purchasing an additional 1,279 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Jade Biosciences by 16.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 12,097 shares of the company’s stock worth $187,000 after purchasing an additional 1,709 shares during the last quarter.

Jade Biosciences Company Profile

(Get Free Report)

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.